The use of radioactive iodine (RAI) for patients with thyroid cancer (TC) who are also treated with hemodialysis for end-stage renal disease (HD-ESRD) remains challenging, with several issues still ...

PET is a powerful molecular imaging technique that can provide functional information on living objects. However, the spatial resolution of PET imaging has been limited to around 1 mm, which makes it ...

Dosimetry in peptide receptor radionuclide therapy using 177Lu-DOTATATE is based on patient imaging during the first week after administration and determination of the activity retention as a function ...

Metastasis-directed therapy (MDT) in oligometastatic renal cell carcinoma (RCC) is typically based on conventional imaging. Prostate-specific membrane antigen (PSMA) PET/CT has shown superiority over ...

The translation of radiolabeled tumor-targeting peptides into clinical routine is often hampered by an enhanced accumulation into the excreting organs. It has recently been reported that the (EH)3 ...

Resection of tumors using targeted dual-modality probes combining preoperative imaging with intraoperative guidance is of high clinical relevance and might considerably affect the outcome of prostate ...

Multicenter oncology clinical trials are increasingly using PET/CT imaging as primary and secondary endpoints to define success or failure of treatment regimens, with considerable effort expended in ...

Personalization of treatment response through the use of on-treatment biomarkers is the future of theranostics and marks a key advantage of theranostics treatments over other systemic cancer therapies ...

Objective response evaluation in oncologic disease is a key endpoint of patient outcome. Response assessment has been performed using tumor measurements at the individual lesion level. For example, ...

Journal of Nuclear Medicine April 2026, jnumed.126.272026; DOI: https://doi.org/10.2967/jnumed.126.272026 As radiopharmaceutical therapy (RPT) expands beyond ...

Journal of Nuclear Medicine May 2026, jnumed.125.271348; DOI: https://doi.org/10.2967/jnumed.125.271348 ...

Anti–programmed death 1 (PD-1) inhibitors are the standard of care for advanced gastroesophageal cancer. Although recommendations and approval by regulatory agencies are often based on programmed ...